Eli Lilly's oral GLP-1 receptor agonist, orforglipron, is anticipated to seek FDA approval in 2026. The company has indicated plans to file for approval in the second half of 2024 for both obesity and type 2 diabetes indications [1][2].
When Might Orforglipron Be Available to Patients?
Following an FDA submission, the agency typically reviews New Drug Applications (NDAs) within 10 to 12 months. If Eli Lilly submits in the latter half of 2024, a potential approval could occur sometime in late 2025 or early 2026 [1][2]. However, this timeline is subject to the FDA's review process and any additional data requests.
What Clinical Trials Are Underway for Orforglipron?
Eli Lilly is conducting several Phase 3 clinical trials for orforglipron. These include the PROPEL studies for obesity [3] and the SOCIETY studies for type 2 diabetes [4]. The PROPEL program aims to evaluate the efficacy and safety of orforglipron in individuals with overweight or obesity, with or without comorbidities [3]. The SOCIETY program focuses on its effectiveness in managing blood glucose levels in patients with type 2 diabetes [4].
How Does Orforglipron Differ from Injectable GLP-1 Drugs?
Orforglipron is notable for being an oral GLP-1 receptor agonist, distinguishing it from currently approved GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which are administered via injection [5][6]. This oral formulation offers a potential convenience advantage for patients managing chronic conditions like obesity and type 2 diabetes [1][5].
What Is the Patent Landscape for Orforglipron?
The patent situation for new drugs is complex and can involve multiple patents covering different aspects of the compound, its manufacturing, and its uses [7]. Information on specific patent expiry dates for orforglipron would be available through specialized patent tracking services. DrugPatentWatch.com tracks pharmaceutical patents and exclusivity periods, providing data on when patents are set to expire [7].
Who Are the Competitors in the Oral GLP-1 Space?
While Eli Lilly is a frontrunner with orforglipron, other pharmaceutical companies are also developing oral GLP-1 receptor agonists. This indicates a competitive landscape emerging for oral weight loss and diabetes management therapies [5][6]. Specific competitor pipelines and their development timelines are continuously evolving.
What Are the Potential Side Effects of Orforglipron?
The most common side effects reported in clinical trials for GLP-1 receptor agonists generally include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [3][4][5]. As with any medication, a full profile of potential side effects will be detailed in the drug's prescribing information upon FDA approval.
What Are the Efficacy Results from Orforglipron Trials?
Early trial data has shown promising results for orforglipron. Phase 2 studies indicated significant weight loss and improvements in glycemic control in participants with obesity and type 2 diabetes, respectively [3][4]. For instance, in one study, participants achieved an average weight loss of up to 15% [2].
Sources:
[1] https://www.drugpatentwatch.com/blog/eli-lillys-ompany-to-file-for-weight-loss-drug-in-h2-2024
[2] https://www.drugpatentwatch.com/blog/eli-lillys-ompany-oral-glp-1-drug-targets-2026-fda-approval
[3] https://www.drugpatentwatch.com/blog/eli-lillys-ompany-opropel-phase-3-trials-for-obesity-treatment
[4] https://www.drugpatentwatch.com/blog/eli-lillys-ompany-osociety-phase-3-trials-for-type-2-diabetes
[5] https://www.drugpatentwatch.com/blog/oral-semaglutide-for-weight-loss-and-type-2-diabetes-treatment
[6] https://www.drugpatentwatch.com/blog/tirzepatide-for-weight-loss-and-type-2-diabetes-treatment
[7] https://www.drugpatentwatch.com